Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

The Newswire – August 18, 2026 - CTT Pharmaceutical Holdings, Inc. (OTCQB:CTTH) has filed a patent continuation with the United States Patent Office. This patent application is a continuation of CTT Pharma's micelle patent in the U.S. and introduces additional claims to pursue broader protection. CTT will continue to spend time enhancing it's patent portfolio and will keep shareholders posted on all additional patent information as it becomes available. About CTT Pharmaceutical Holdings, Inc.

August 12, 2026 – TheNewswire - CTT Pharmaceutical Holdings, Inc. (OTCQB:CTTH) has been looking to acquire a facility for manufacturing and has recently expanded its search for a partnership with a contract manufacturer. CTT is currently engaged in conversations with a contract manufacturer and will update shareholders if an LOI is signed. Additionally, CTT is in advanced contract discussions with an Investor Relations(IR) and a Public Relations(PR) Firm that would handle the company's future exposure.

August 10, 2026 – TheNewswire - CTT Pharmaceutical Holdings, Inc. (OTCQB:CTTH) is pleased to announce the company has been formally approved by the U.S. Patent Office for a continuation-in-part(CIP). A continuation-in-part (CIP) patent is a new application that repeats a substantial portion of an earlier “parent” application while adding brand new subject matter or improvements. The U.S. Patent Office has issued a patent number and will issue the patent on August 11, 2026. The CIP patent adds additional protection for nicotine, vitamins, and caffeine  utilizing our micelle delivery technology. This new patent allows CTT Pharma the ability to use our technology to make dissolvable strips, gum, pouches, lozenges, and dissolving tablets. CTT will continue to spend time strengthening our patent portfolio as the company believes patents are an important aspect of the business. About CTT Pharmaceutical Holdings, Inc.

August 5, 2026 – TheNewswire - CTT Pharmaceutical Holdings, Inc. (OTCQB:CTTH) is pleased to announce the company has been formally approved by the SEC for our S-1 and will now be a SEC reporting company. This is an important milestone as CTT Pharma is now an audited, SEC reporting company on the OTCQB and will start filing an SEC form 8-K when material events occur. CTT will update shareholders as more news becomes available.   About CTT Pharmaceutical Holdings, Inc.